ISSN:
1573-0646
Keywords:
oral cytotoxic
;
4-demethoxydaunorubicin
;
idarubicin
;
non-small cell lung cancer
;
phase II clinical trial
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Abstract Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00179596
Permalink